Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1960353 | 0.86 | KDM4E (0.38) | KDM5BKDM4ESMN1; SMN2KCNH2IDO1 | |
| SCHEMBL16628721 | 0.83 | KCNH2 (0.42) | KDM5BKDM4ESMN1; SMN2KCNH2CYP19A1 | |
| SCHEMBL2343622 | 0.82 | KCNH2 (0.40) | KDM5BKDM4ESMN1; SMN2KCNH2IDO1 | |
| SCHEMBL1961171 | 0.80 | KDM4E (0.37) | KDM5BKDM4ESMN1; SMN2KCNH2IDO1 | |
| SCHEMBL13463409 | 0.79 | KCNH2 (0.40) | KDM5BKDM4EKCNH2 | |
| SCHEMBL1959831 | 0.79 | CYP11B1 (0.42) | CYP11B1CYP19A1 | |
| SCHEMBL13463859 | 0.78 | KCNH2 (0.47) | KDM5BKCNH2 | |
| SCHEMBL1960587 | 0.78 | KDM4A (0.45) | KDM5BKCNH2 | |
| SCHEMBL1961113 | 0.77 | NPC1 (0.49) | SMN1; SMN2CYP11B1DPP4 | |
| SCHEMBL26087174 | 0.77 | KCNH2 (0.54) | KDM4ESMN1; SMN2CYP11B1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779141-B2 | Viral inhibitors | GILEAD SCIENCES, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-1521754-B1 | VIRAL INHIBITORS | LEUVEN K U RES & DEV (BE) | 2011-08-31 | — | — | EP | disclosed |
| EP-2332938-A1 | Viral inhibitors | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2011-06-15 | — | — | EP | disclosed |
| US-7737162-B2 | Viral inhibitors | GILEAD SCIENCES, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100004281-A1 | VIRAL INHIBITORS | GILEAD SCIENCES, INC. | 2010-01-07 | — | — | US | disclosed |
| US-20050239821-A1 | Viral inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2005-10-27 | — | — | US | disclosed |
| EP-1521754-A2 | VIRAL INHIBITORS | K.U.Leuven Research & Development (BE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004005286-A2 | VIRAL INHIBITORS | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004281-A1 | VIRAL INHIBITORS | ZC3HAV1, MAVS, HAVCR2 | KDM5B 590/4885KCNK3 4191/4885KDM4E 519/4885 |
| US-20050239821-A1 | Viral inhibitors | ZC3HAV1, ZC3HAV1L, ACE | KDM5B 963/4885KCNK3 3833/4885KDM4E 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.